Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT‐CN study
Authors' conclusion
Early weight loss with tirzepatide was associated with significant improvements in cardiometabolic risk factors, particularly in Chinese adults achieving a normal BMI by week 52, suggesting that early response may be associated with enhanced long-term metabolic health outcomes.
Study context
- Population
- Chinese adults in SURMOUNT-CN, categorized by Chinese-specific body mass index (BMI) and waist circumference cutoffs
- Participants
- 177 adults
- Comparison
- Tirzepatide 10 mg and 15 mg vs placebo
- Tirzepatide 10 mgn = 62
- Tirzepatide 15 mgn = 57
- Placebon = 58reference
Primary result
As reported in the abstract
Cardiometabolic markers and metabolic syndrome by early weight loss and BMI subgroup · week 52
Participants achieving normal BMI (18.5-24 kg/m², Chinese criteria) at week 52
37
Metabolic syndrome in those achieving normal BMI, baseline to week 52
21.6% to 0%
Further findings
| Outcome | P value |
|---|---|
| Body weight, BMI and waist circumferenceTirzepatide vs Placebo · significantly reduced with tirzepatide | P < 0.05 |
Original publication
Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT‐CN study. Obesity (Silver Spring). Published 28 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →